Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting APOC3 in the familial chylomicronemia syndrome.

The New England journal of medicine - 4 Dec 2014

Gaudet Daniel, Brisson Diane, Tremblay Karine, Alexander Veronica J, Singleton Walter, Hughes Steven G, Geary Richard S, Baker Brenda F, Graham Mark J, Crooke Rosanne M, Witztum Joseph L

Abstract excerpt

The familial chylomicronemia syndrome is a genetic disorder characterized by severe hypertriglyceridemia and recurrent pancreatitis due to a deficiency in lipoprotein lipase (LPL). Currently, there are no effective therapies except for extreme restriction in the consumption of dietary fat. Apolipoprotein C-III (APOC3) is known to inhibit LPL, although there is also evidence that APOC3 increases the level of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apolipoprotein C-III
Share to APOC3 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hyperlipoproteinemia Type I

Share to Lipoprotein Lipase

Share to Mutation

Share to Oligonucleotides

Share to RNA, Messenger

Share to Triglycerides

Source

Identifiers

PMID: 25470695
DOI: 10.1056/NEJMoa1400284

Genes

APOC3
LPL

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting APOC3 in the familial chylomicronemia syndrome.PMID 25470695Read ↗

Clinical identification of familial chylomicronemia syndrome and novel therapeutic options.Semantic proximity Read ↗

Novel Therapeutics for Familial Chylomicronemia SyndromeSemantic proximity Read ↗

Effect of olezarsen on lipoprotein-associated ApoC-III levels in patients with familial chylomicronemia syndromeSemantic proximity Read ↗

Familial chylomicronemia syndrome and treatments to target hepatic APOC3 mRNASemantic proximity Read ↗

ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors.Semantic proximity Read ↗

Drug target Mendelian randomization supports apolipoprotein C3-lowering for lipoprotein-lipid levels reductions and cardiovascular diseases prevention.Semantic proximity Read ↗

[Mutations of APOC3 gene, metabolism of triglycerides and reduction of ischemic cardiovascular events].Semantic proximity Read ↗

A Novel APOC2 Missense Mutation Causing Apolipoprotein C-II Deficiency With Severe Triglyceridemia and PancreatitisSemantic proximity Read ↗

Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease.Semantic proximity Read ↗

Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial.Semantic proximity Read ↗

Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism.Semantic proximity Read ↗

Apolipoprotein CIII overexpressing mice are predisposed to diet-induced hepatic steatosis and hepatic insulin resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.